Today: 10 June 2026
Browse Category

NASDAQ:CLDX 26 February 2026

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics shares fell about 4% to $29.58 in premarket trading Thursday, after surging 24% the previous session. The company completed enrollment in two global Phase 3 barzolvolimab studies for chronic spontaneous urticaria six months ahead of schedule. Topline data are expected in Q4 2026, with a U.S. BLA filing planned for 2027. Celldex ended 2025 with $518.6 million in cash and posted a full-year net loss of $258.8 million.

Stock Market Today

  • AutoNation (AN) Shares Rise Amid Mixed Fair Value Signals, Analysts See 20% Undervaluation
    June 10, 2026, 10:19 AM EDT. AutoNation (AN) shares gained 4.9% in one day and 2.0% over the past week, though they are down 5.6% year-to-date, contrasting with a 5-year total shareholder return of 107.4%. Despite recent share price momentum cooling, analysts see potential value, assigning a consensus price target of $242.75, about 20% above the recent $195.0 closing price. Price targets vary between $208.0 and $300.0, reflecting uncertainty over earnings sustainability and market multiples. The company shows steady revenue and net income growth, but future margin pressures remain due to competition from direct-to-consumer models and faster electric vehicle adoption. The fair value estimate hinges on the traditional dealership model retaining its competitive edge. This mixed outlook highlights investor caution amid evolving automotive market dynamics.

Latest articles

Go toTop